Medical treatment of Parkinson's disease

Acta Neurologica Taiwanica

Volumn 12, Issue 1, 2003, Pages 43-57

  Hwang, Wen Juh ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Anticholinergic drugs; Dopamine receptor agonists; Dopaminergic drugs; Medical treatment; Parkinson's disease

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADVERSE DRUG REACTION; AGE; CLINICAL FEATURE; COGNITION; COMORBIDITY; DIAGNOSTIC ACCURACY; EMPLOYABILITY; EVIDENCE BASED MEDICINE; FUNCTIONAL DISEASE; HUMAN; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SYMPTOM; TREATMENT PLANNING;

EID: 0037347870     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Weiner WJ. The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord 1999;14:716-24.
2. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999;14:725-30.
3. Rajput AH, Fenton ME, Birdi S, et al. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-8.
4. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 2001;56:S1-88.
5. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130-43.
6. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000;47:S167-78.
7. Hwang WJ, Yao WJ, Wey SP, et al. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation. Eur Neurol 2002;47:113-7.
8. Nutt JG, Carter JH, Lea ES, et al. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997;12:285-92.
9. Diamond SE, Markham CH, Hoehn MM, et al. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12.
10. Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc 1996;71:659-70.
11. Wang HC, Hsieh Y. Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord 2001;16:765-7.
12. Frucht S, Rogers JD, Greene PE, et al, Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-10.
13. Ferreira JJ, Galitzky M, Montastruc JL, et al. Sleep attacks and Parkinson's disease treatment. Lancet 2000;355:1333-4.
14. Colosimo C. The rise and fall of tolcapone. J Neurol 1999;246:880-2.
15. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
16. Garcia-Monco JC, Padierna A, Beldarrain MG. Selegiline, fluoxetine, and depression in Parkinson's disease. Mov Disord 1995;10:352.
17. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
18. Schwab RS, England AC Jr, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969;208:1168-70.
19. Rajput AH, Rajput A, Lang AE, et al. New use of an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord 1998;13:851.
20. Bum DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002;17:445-54.
21. Friedman JH, Factors SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-11.